Structures by: Yathirajan H. S.
Total: 746
1-(4-Azidophenyl)-3-[5-(2,4-dichlorophenoxy)-3-methyl-1-phenyl-1<i>H</i>-pyrazol-4-yl]prop-2-en-1-one
C25H17Cl2N5O2
Acta Crystallographica Section E (2020) 76, 5 683-691
a=28.1916(17)Å b=8.0537(5)Å c=22.0446(12)Å
α=90° β=109.0700(10)° γ=90°
1-(4-Azidophenyl)-3-[3-methyl-5-(naphthalen-2-yloxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]prop-2-en-1-on
C29H21N5O2
Acta Crystallographica Section E (2020) 76, 5 683-691
a=9.8460(8)Å b=22.4303(18)Å c=11.0490(9)Å
α=90° β=104.157(2)° γ=90°
<i>N</i>-(4-Methoxyphenyl)piperazine
C11H16N2O
Acta Crystallographica Section E (2020) 76, 4 488-495
a=6.9683(7)Å b=7.9683(8)Å c=18.975(2)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 3,5-dinitrobenzoate
C11H17N2O,C7H3N2O6
Acta Crystallographica Section E (2020) 76, 4 488-495
a=7.4365(4)Å b=10.6276(6)Å c=13.2700(6)Å
α=92.238(4)° β=97.057(4)° γ=108.618(5)°
4-(4-Methoxyphenyl)piperazin-1-ium 2,4,6-trinitrophenolate
C11H17N2O,C6H2N3O7
Acta Crystallographica Section E (2020) 76, 4 488-495
a=8.7568(6)Å b=6.6292(5)Å c=34.024(2)Å
α=90° β=96.987(6)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-aminobenzoate monohydrate
C7H6NO2,C11H17N2O,H2O
Acta Crystallographica Section E (2020) 76, 4 488-495
a=6.2590(7)Å b=7.4549(9)Å c=19.269(2)Å
α=83.280(10)° β=84.7400(10)° γ=85.380(10)°
1-(4-Bromophenyl)-3-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C18H13BrO2
Acta Crystallographica Section E (2020) 76, 3 360-365
a=18.286(6)Å b=14.277(4)Å c=5.8489(17)Å
α=90° β=94.521(7)° γ=90°
1-(4-Chlorophenyl)-3-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C18H13ClO2
Acta Crystallographica Section E (2020) 76, 3 360-365
a=17.990(3)Å b=14.2529(16)Å c=5.8661(8)Å
α=90° β=94.419(4)° γ=90°
(<i>RS</i>)-3-(4-Bromophenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C19H16BrN3OS
Acta Crystallographica Section E (2020) 76, 3 360-365
a=15.1255(13)Å b=6.0426(5)Å c=21.026(2)Å
α=90° β=110.555(3)° γ=90°
(<i>RS</i>)-3-(4-Chlorophenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C19H16ClN3OS
Acta Crystallographica Section E (2020) 76, 3 360-365
a=15.0182(9)Å b=6.0579(3)Å c=20.8286(12)Å
α=90° β=110.573(2)° γ=90°
(<i>RS</i>)-3-(4-Methoxyphenyl)-5-[4-(prop-2-ynyloxy)phenyl]-4,5-dihydropyrazole-1-carbothioamide
C20H19N3O2S
Acta Crystallographica Section E (2020) 76, 3 360-365
a=11.7852(15)Å b=7.5345(11)Å c=20.599(3)Å
α=90° β=93.555(4)° γ=90°
2-(4-Chlorobenzyl)-6-(4-fluorophenyl)-5-[(1<i>H</i>-indol-3-yl)methyl]imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H18ClFN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=15.3400(10)Å b=11.1619(7)Å c=15.3850(10)Å
α=90° β=119.480(10)° γ=90°
2-(4-Chlorobenzyl)-5-[(1<i>H</i>-indol-3-yl)methyl]-6-phenylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H19ClN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=16.456(7)Å b=10.420(2)Å c=26.391(7)Å
α=90° β=90.031(12)° γ=90°
6-(4-Bromophenyl)-2-(4-chlorobenzyl)-5-[(1<i>H</i>-indol-3-yl)methyl]imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H18BrClN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=9.5735(8)Å b=9.6860(9)Å c=25.644(2)Å
α=90° β=90° γ=90°
3-(3-Methyl-5-phenoxy-1-phenyl-1<i>H</i>-pyrazol-4-yl)-1-(thiophen-2-yl)prop-2-en-1-one
C23H18N2O2S
Acta Crystallographica Section E (2020) 76, 1 48-52
a=9.6158(5)Å b=19.8846(11)Å c=10.3773(6)Å
α=90° β=93.712(2)° γ=90°
3-[3-Methyl-5-(2-methylphenoxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-(thiophen-2-yl)prop-2-en-1-one
C24H20N2O2S
Acta Crystallographica Section E (2020) 76, 1 48-52
a=9.4336(4)Å b=20.6071(9)Å c=10.5866(4)Å
α=90° β=93.106(2)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-bromobenzoate monohydrate
C11H17N2O,C7H4BrO2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2004(8)Å b=7.4957(9)Å c=20.440(2)Å
α=85.080(10)° β=87.370(10)° γ=85.000(10)°
4-(4-Methoxyphenyl)piperazin-1-ium 2-hydroxybenzoate
C11H17N2O,C7H5O3
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.5009(8)Å b=7.9735(9)Å c=32.155(4)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 2-hydroxy-3,5-dinitrobenzoate
C7H3N2O7,C11H17N2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=7.5500(9)Å b=7.6489(9)Å c=32.719(6)Å
α=90° β=91.300(10)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogensuccinate
C11H17N2O,C4H5O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.3225(9)Å b=28.261(3)Å c=5.8228(8)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium pyridine-3-carboxylate
C11H17N2O,C6H4NO2
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.2817(7)Å b=11.2905(7)Å c=30.309(2)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogenfumarate
C11H17N2O,C4H3O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.0690(10)Å b=28.528(3)Å c=5.8375(9)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogenmaleate
C11H17N2O,C4H3O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.0630(10)Å b=6.4956(9)Å c=26.093(3)Å
α=90° β=93.180(10)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium trichloroacetate
C11H17N2O,C2Cl3O2
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=10.6117(11)Å b=13.8080(10)Å c=10.9137(8)Å
α=90° β=90° γ=90°
Bis(4-(4-methoxyphenyl)piperazin-1-ium) chloranilate(2-) dihydrate
C11H17N2O,0.5(C6Cl2O4),H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.1597(5)Å b=15.1434(8)Å c=10.8742(6)Å
α=90° β=102.067(5)° γ=90°
(<i>E</i>)-2-Ethyl-<i>N</i>-(4-nitrobenzylidene)aniline
C15H14N2O2
Acta Crystallographica Section E (2018) 74, 8 1071-1074
a=7.6419(7)Å b=11.8889(13)Å c=14.8082(16)Å
α=90° β=90° γ=90°
1-Phenyl-1<i>H</i>-pyrazole-3,4-dicarboxylic acid
C11H8N2O4
Acta Crystallographica Section E (2018) 74, 12 1783-1789
a=13.164(2)Å b=7.4692(9)Å c=21.173(3)Å
α=90° β=90° γ=90°
Dimethyl 1-phenyl-1<i>H</i>-pyrazole-3,4-dicarboxylate
C13H12N2O4
Acta Crystallographica Section E (2018) 74, 12 1783-1789
a=5.9000(4)Å b=14.5273(12)Å c=14.8726(12)Å
α=90° β=98.867(3)° γ=90°
Dimethyl 1-(4-methylphenyl)-1<i>H</i>-pyrazole-3,4-dicarboxylate
C14H14N2O4
Acta Crystallographica Section E (2018) 74, 12 1783-1789
a=7.6546(5)Å b=8.0959(5)Å c=11.3065(6)Å
α=78.988(3)° β=85.527(3)° γ=87.548(4)°
Clozapinium 3,5-dinitrobenzoate dimethyl sulfoxide monosolvate
C18H20ClN4,C7H3N2O6,C2H6OS
Acta Crystallographica Section E (2015) 71, 4 406-413
a=15.3593(2)Å b=15.7685(2)Å c=11.8679(2)Å
α=90° β=91.8097(14)° γ=90°
Clozapinium hydrogen maleate 0.21-hydrate
C18H20ClN4,C4H3O4,0.21(H2O)
Acta Crystallographica Section E (2015) 71, 4 406-413
a=9.7166(3)Å b=9.9699(2)Å c=23.1059(6)Å
α=90° β=96.800(3)° γ=90°
Clozapinium 2-hydroxybenzoate
C18H20ClN4,C7H5O3
Acta Crystallographica Section E (2015) 71, 4 406-413
a=17.4296(5)Å b=15.3728(5)Å c=8.6359(3)Å
α=90° β=90.325(3)° γ=90°
Methyl 5-bromo-2-[(2-chloroquinolin-3-yl)methoxy]benzoate
C18H13BrClNO3
Acta Crystallographica Section E (2015) 71, 6 609-617
a=7.3185(4)Å b=18.4177(7)Å c=11.7870(5)Å
α=90° β=93.609(4)° γ=90°
2-Chloro-3-[(naphthalen-1-yloxy)methyl]quinoline
C20H14ClNO
Acta Crystallographica Section E (2015) 71, 6 609-617
a=5.3165(3)Å b=10.5098(4)Å c=13.6201(7)Å
α=90° β=98.527(5)° γ=90°
Methyl 5-bromo-2-[(2-chloro-6-methylquinolin-3-yl)methoxy]benzoate
C19H15BrClNO3
Acta Crystallographica Section E (2015) 71, 6 609-617
a=15.1920(3)Å b=11.98641(19)Å c=19.0307(3)Å
α=90° β=90° γ=90°
Methyl 2-[(2-chloro-6-methylquinolin-3-yl)methoxy]benzoate
C19H16ClNO3
Acta Crystallographica Section E (2015) 71, 6 609-617
a=13.5860(3)Å b=15.5857(2)Å c=30.9389(5)Å
α=90° β=90° γ=90°
{5-[(2-Chloroquinolin-3-yl)methoxy]-4-(hydroxymethyl)-6-methyl-pyridin-3-yl}methanol
C18H17ClN2O3
Acta Crystallographica Section E (2015) 71, 6 609-617
a=9.7866(3)Å b=15.3336(4)Å c=10.6570(3)Å
α=90° β=92.381(3)° γ=90°
3-Chloro-2-(4-methylphenyl)-2<i>H</i>-pyrazolo[3,4-<i>b</i>]quinoline
C17H12ClN3
Acta Crystallographica Section E (2015) 71, 5 567-570
a=10.2194(4)Å b=13.4661(5)Å c=10.4600(4)Å
α=90° β=102.780(4)° γ=90°
2-Chloro-3-(dimethoxymethyl)-6-methoxyquinoline
C13H14ClNO3
Acta Crystallographica Section E (2015) 71, 5 o364-o365
a=27.1156(9)Å b=7.1401(3)Å c=13.0804(5)Å
α=90° β=90° γ=90°
2-(4-Chlorophenyl)-<i>N</i>-(2-iodophenyl)acetamide
C14H11ClINO
Acta Crystallographica Section E (2016) 72, 9 1270-1275
a=24.0010(10)Å b=6.2369(3)Å c=9.3266(4)Å
α=90° β=99.621(2)° γ=90°
2-(4-Chlorophenyl)-<i>N</i>-(pyrazin-2-yl)acetamide
C12H10ClN3O
Acta Crystallographica Section E (2016) 72, 9 1270-1275
a=10.7041(4)Å b=7.5724(3)Å c=28.6619(11)Å
α=90° β=90° γ=90°
Trihexyphenidylium 3,5-dinitrobenzoate
C20H32NO,C7H3N2O6
Acta Crystallographica Section E (2019) 75, 2 292-298
a=11.2743(12)Å b=11.2898(12)Å c=12.6478(13)Å
α=111.9230(10)° β=114.3250(10)° γ=95.9030(10)°
[3-(2-Chloro-9<i>H</i>-thioxanthen-9-yl)propyl]dimethylammonium hydrogen bis(3,5-dinitrobenzoate)
C18H19ClNS,C7H3N2O6,C7H4N2O6
Acta Crystallographica Section E (2019) 75, 2 292-298
a=11.3454(8)Å b=24.3857(16)Å c=11.6098(8)Å
α=90° β=93.6910(10)° γ=90°
1-(2-Iodobenzoyl)-4-(pyrimidin-2-yl)piperazine
C15H15IN4O
Acta Crystallographica Section E (2019) 75, 2 129-133
a=9.6417(17)Å b=13.604(2)Å c=12.174(2)Å
α=90° β=105.155(2)° γ=90°
1-[(1,3-Benzodioxol-5-yl)methyl]-4-(2,6-difluorobenzoyl)piperazine
C19H18F2N2O3
Acta Crystallographica Section E (2019) 75, 2 202-207
a=14.2762(9)Å b=15.9821(10)Å c=7.3753(5)Å
α=90° β=90° γ=90°
1-[(1,3-Benzodioxol-5-yl)methyl]-4-(3-fluorobenzoyl)piperazine
C19H19FN2O3
Acta Crystallographica Section E (2019) 75, 2 202-207
a=12.2358(16)Å b=10.3185(14)Å c=14.2310(19)Å
α=90° β=111.199(2)° γ=90°
1-[(1,3-Benzodioxol-5-yl)methyl]-4-(2,4-dichlorobenzoyl)piperazine
C19H18Cl2N2O3
Acta Crystallographica Section E (2019) 75, 2 202-207
a=12.2889(14)Å b=12.3034(14)Å c=13.3667(15)Å
α=90° β=116.2950(10)° γ=90°
(<i>RS</i>)-7-Chloro-2-(2,5-dimethoxyphenyl)-2,3-dihydroquinazolin-4(1<i>H</i>)-one
C16H15ClN2O3
Acta Crystallographica Section E (2019) 75, 6 843-847
a=15.314(7)Å b=15.314(7)Å c=25.736(12)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-chlorobenzoate monohydrate
C11H17N2O,C7H4ClO2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2110(10)Å b=7.4810(10)Å c=20.144(4)Å
α=84.90(2)° β=87.48(2)° γ=85.19(2)°
4-(4-Methoxyphenyl)piperazin-1-ium benzoate monohydrate
C11H17N2O,C7H5O2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2150(10)Å b=7.5470(10)Å c=18.716(4)Å
α=84.34(2)° β=87.14(2)° γ=84.69(2)°
4-(4-Methoxyphenyl)piperazin-1-ium 4-fluorobenzoate monohydrate
C11H17N2O,C7H4FO2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2560(10)Å b=7.4890(10)Å c=19.097(2)Å
α=84.190(10)° β=86.98(2)° γ=84.62(2)°
1-Benzoyl-4-(4-methoxyphenyl)piperazine
C18H20N2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=29.403(5)Å b=7.9811(14)Å c=6.7898(13)Å
α=90° β=97.352(12)° γ=90°
1-(2-Fluorobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19FN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=6.998(2)Å b=7.938(2)Å c=28.415(6)Å
α=90° β=92.20(3)° γ=90°
1-(2-Chlorobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19ClN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=13.0320(11)Å b=13.2470(13)Å c=19.258(2)Å
α=90° β=90° γ=90°
1-(2-Iodobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19IN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=12.7671(13)Å b=13.5429(12)Å c=20.2542(16)Å
α=90° β=90° γ=90°
1-(2-Hydroxybenzoyl)-4-(4-methoxyphenyl)piperazine
C18H20N2O3
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=9.7265(6)Å b=12.9084(9)Å c=24.8610(10)Å
α=90° β=90° γ=90°
1-(2-Bromoobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19BrN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=12.9119(14)Å b=13.3664(16)Å c=19.5019(19)Å
α=90° β=90° γ=90°
(2<i>E</i>)-1-(5-Chlorothiophen-2-yl)-3-(2-methylphenyl)prop-2-en-1-one
C14H11ClOS
Acta Crystallographica Section E (2016) 72, 8 1153-1158
a=14.7179(7)Å b=7.5783(4)Å c=11.5451(5)Å
α=90° β=102.999(4)° γ=90°
2-Benzoylamino-<i>N</i>'-(4-hydroxybenzylidene)-3-(thiophen-2-yl)prop-2-enohydrazide
C21H17N3O3S
Acta Crystallographica Section E (2016) 72, 8 1099-1102
a=22.5212(7)Å b=10.1879(4)Å c=17.3592(5)Å
α=90° β=105.801(3)° γ=90°
(2<i>E</i>)-1-(Anthracen-9-yl)-3-[4-(propan-2-yl)phenyl]prop-2-en-1-one
C26H22O
Acta Crystallographica Section E (2016) 72, 8 1153-1158
a=9.0150(4)Å b=14.0601(6)Å c=16.2611(8)Å
α=105.146(4)° β=95.967(4)° γ=98.057(4)°
6-Hydroxy-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4(3<i>H</i>)-one
C15H12N4O4
Acta Crystallographica Section E (2016) 72, 7 969-971
a=12.1863(9)Å b=10.7079(8)Å c=11.1726(8)Å
α=90° β=105.412(8)° γ=90°
2-Amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium benzoate
C11H19N2S,C7H5O2
Acta Crystallographica Section E (2017) 73, 9 1320-1325
a=10.6089(3)Å b=22.7141(5)Å c=8.8959(2)Å
α=90° β=122.2110(10)° γ=90°
2-Amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium picrate
C11H19N2S,C6H2N3O7
Acta Crystallographica Section E (2017) 73, 9 1320-1325
a=10.7928(2)Å b=6.95910(10)Å c=28.0176(5)Å
α=90° β=97.4080(10)° γ=90°
<i>N</i>-(4-chlorobenzylidene)-2-hydroxyaniline
C13H10ClNO
Acta Crystallographica Section E (2018) 74, 3 376-379
a=13.0830(17)Å b=5.8746(6)Å c=14.825(2)Å
α=90° β=101.521(4)° γ=90°
(<i>RS</i>)-(4-Chlorophenyl)(pyridin-2-yl)methanol
C12H10ClNO
Acta Crystallographica Section E (2016) 72, 1 69-72
a=8.4309(6)Å b=16.1488(11)Å c=8.6878(6)Å
α=90° β=112.994(2)° γ=90°
Ethyl (1<i>RS</i>,6<i>SR</i>)-4-(2-methyl-1<i>H</i>-imidazol-4-yl)-2-oxo-6-(2,3,5-trichlorophenyl)cyclohex-3-ene-1-carboxylate
C19H17Cl3N2O3
Acta Crystallographica Section E (2016) 72, 1 31-34
a=9.753(5)Å b=10.029(6)Å c=11.099(5)Å
α=106.281(4)° β=96.420(5)° γ=104.913(5)°
3-Benzoyl-2-[(5-bromo-2-hydroxy-3-methoxybenzylidene)amino]-4,5,6,7-tetrahydrobenzo[<i>b</i>]thiophene
C23H20BrNO3S
Acta Crystallographica Section E (2015) 71, 2 176-179
a=4.81267(18)Å b=22.1919(8)Å c=18.7012(7)Å
α=90° β=97.392(3)° γ=90°
4-Amino-3-methyl-1<i>H</i>-1,2,4-triazole-5(4<i>H</i>)-thione
C3H6N4S
Acta Crystallographica Section E (2015) 71, 9 1003-1009
a=8.8682(6)Å b=9.8230(6)Å c=6.5427(4)Å
α=90° β=90° γ=90°
4-[(<i>E</i>)-(3,4-Dimethoxybenzylidene)amino]-3-methyl-1<i>H</i>-1,2,4-triazole-5(4<i>H</i>)-thione
C12H14N4O2S
Acta Crystallographica Section E (2015) 71, 9 1003-1009
a=7.3112(4)Å b=16.0793(9)Å c=22.8994(13)Å
α=90° β=90° γ=90°
4-[(<i>E</i>)-(5-Bromo-2-hydroxybenzylidene)amino]-3-methyl-1<i>H</i>-1,2,4-triazole-5(4<i>H</i>)-thione
C10H9BrN4OS
Acta Crystallographica Section E (2015) 71, 9 1003-1009
a=4.4122(4)Å b=14.7450(13)Å c=18.7911(16)Å
α=90° β=95.828(3)° γ=90°
(2<i>E</i>)-1-(3-Bromothiophen-2-yl)-3-(2-methoxyphenyl)prop-2-en-1-one
C14H11BrO2S
Acta Crystallographica Section E (2015) 71, 8 966-972
a=11.2517(4)Å b=14.5397(6)Å c=16.7857(6)Å
α=76.561(3)° β=89.989(3)° γ=78.836(3)°
(2<i>E</i>)-1-(3-Bromothiophen-2-yl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one
C15H13BrO3S
Acta Crystallographica Section E (2015) 71, 8 966-972
a=13.4748(7)Å b=8.3853(3)Å c=25.0214(9)Å
α=90° β=93.957(4)° γ=90°
Bis-[1-(3-chlorophenyl)piperazinium]dipicrate picric acid
2(C10H14ClN2),2(C6H2N3O7),C6H3N3O7
Acta Crystallographica Section E (2014) 70, 11 o1210-o1211
a=11.2213(6)Å b=14.6239(7)Å c=14.1804(8)Å
α=90° β=104.405(5)° γ=90°
(2<i>E</i>)-1-(5-Chlorothiophen-2-yl)-3-(4-ethylphenyl)prop-2-en-1-one
C15H13ClOS
Acta Crystallographica Section E (2015) 71, 9 1093-1099
a=6.0154(5)Å b=8.6358(5)Å c=14.0548(9)Å
α=74.428(5)° β=88.225(6)° γ=70.417(6)°
(2E)-1-(5-Bromothiophen-2-yl)-3-(4-ethylphenyl)prop-2-en-1-one
C15H13BrOS
Acta Crystallographica Section E (2015) 71, 9 1093-1099
a=5.9745(6)Å b=8.6636(7)Å c=14.3039(12)Å
α=74.731(7)° β=88.146(7)° γ=70.334(8)°
(2<i>E</i>)-1-(5-Chlorothiophen-2-yl)-3-(4-ethoxyphenyl)prop-2-en-1-one
C15H13ClO2S
Acta Crystallographica Section E (2015) 71, 9 1093-1099
a=16.3577(6)Å b=7.4518(4)Å c=11.0892(4)Å
α=90° β=92.260(3)° γ=90°
(2<i>E</i>)-1-(5-Bromothiophen-2-yl)-3-(4-ethoxyphenyl)prop-2-en-1-one
C15H13BrO2S
Acta Crystallographica Section E (2015) 71, 9 1093-1099
a=16.5498(7)Å b=7.5069(4)Å c=11.1574(5)Å
α=90° β=92.618(4)° γ=90°
(2<i>E</i>)-1-(5-Chlorothiophen-2-yl)-3-(4-bromophenyl)prop-2-en-1-one
C13H8BrClOS
Acta Crystallographica Section E (2015) 71, 9 1093-1099
a=6.0152(8)Å b=8.5691(12)Å c=13.1824(9)Å
α=75.250(10)° β=81.446(8)° γ=70.281(12)°
(2<i>E</i>)-1-(5-Bromothiophen-2-yl)-3-(3-methoxyphenyl)prop-2-en-1-one
C14H11BrO2S
Acta Crystallographica Section E (2015) 71, 9 1093-1099
a=9.2726(6)Å b=11.3948(8)Å c=12.1472(7)Å
α=90° β=93.273(6)° γ=90°
9-[3-(Dimethylamino)propyl]-10,10-dimethyl-9,10-dihydroanthracen-9-ol
C21H27NO
Acta crystallographica. Section E, Structure reports online (2013) 69, Pt 2 o175
a=11.79596(9)Å b=9.17559(7)Å c=16.75788(13)Å
α=90° β=92.2372(7)° γ=90°
6-(2-Chlorophenyl)-2-methylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C11H8ClN3S
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 920-926
a=7.5567(3)Å b=11.4589(5)Å c=24.9006(11)Å
α=90° β=90° γ=90°
6-(2-Chlorophenyl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C10H6ClN3S
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 920-926
a=7.5805(4)Å b=9.7942(5)Å c=13.6175(6)Å
α=97.712(2)° β=96.549(2)° γ=99.416(2)°
6-(3,4-Dichlorophenyl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C10H5Cl2N3S
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 920-926
a=5.5186(2)Å b=7.5194(3)Å c=12.8406(5)Å
α=102.027(2)° β=91.293(2)° γ=98.430(2)°
6-(4-Fluoro-3-methoxyphenyl)-2-methylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C12H10FN3OS
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 920-926
a=8.6766(3)Å b=11.7888(4)Å c=12.5227(4)Å
α=103.039(2)° β=95.189(2)° γ=110.365(2)°
<i>N</i>-(4-Chloro-3-methylphenyl)-2-phenylacetamide
C15H14ClNO
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 889-894
a=5.0039(7)Å b=10.7525(12)Å c=12.6177(12)Å
α=108.615(10)° β=91.771(11)° γ=90.167(11)°
<i>N</i>-(4-Chloro-3-methylphenyl)-2-(2,4-dichlorophenyl)acetamide
C15H12Cl3NO
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 889-894
a=11.8441(7)Å b=4.7288(3)Å c=13.0981(7)Å
α=90° β=101.310(6)° γ=90°
<i>N</i>-(4-Bromo-3-methylphenyl)-2-phenylacetamide
C15H14BrNO
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 889-894
a=4.9995(3)Å b=10.8392(4)Å c=12.7301(7)Å
α=108.149(4)° β=91.968(5)° γ=90.310(4)°
<i>N</i>-(4-Bromo-3-methylphenyl)-2-(2-chlorophenyl)acetamide
C15H13BrClNO
Acta crystallographica. Section C, Structural chemistry (2014) 70, Pt 9 889-894
a=11.8458(8)Å b=4.7282(3)Å c=25.0757(15)Å
α=90° β=98.133(5)° γ=90°
2-Amino-4,4,7,7-tetramethyl-3a,5,6,7a-tetrahydrobenzothiazol-3-ium 4-methylbenzoate
C11H19N2S,C8H7O2
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=10.1879(5)Å b=11.6149(5)Å c=8.7790(4)Å
α=90° β=113.480(6)° γ=90°
2-Amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium 4-bromobenzoate
C11H19N2S,C7H4BrO2
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=10.2506(5)Å b=11.5855(4)Å c=8.8269(4)Å
α=90° β=113.807(6)° γ=90°
2-Amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium 3,5-dinitrobenzoate
C11H19N2S,C7H3N2O6
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=17.3232(6)Å b=5.84087(17)Å c=21.0876(8)Å
α=90° β=109.875(4)° γ=90°
Bis(2-amino-4,4,7,7-tetramethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-3-ium) fumarate
2(C11H19N2S),C4H2O42
Acta crystallographica. Section E, Crystallographic communications (2019) 75, Pt 2 167-174
a=9.0259(6)Å b=14.7314(11)Å c=11.1993(8)Å
α=90° β=101.943(6)° γ=90°
(<i>E</i>)-1-{3-[(5-Fluoro-2-hydroxybenzylidene)amino]phenyl}ethanone
C15H12FNO2
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 12 1835-1839
a=14.9527(5)Å b=5.5152(2)Å c=16.6918(5)Å
α=90° β=114.739(2)° γ=90°
(<i>E</i>)-1-{3-[(2-Hydroxy-3-methoxybenzylidene)amino]phenyl}ethanone
C16H15NO3
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 12 1835-1839
a=19.1904(4)Å b=5.33856(12)Å c=26.5678(6)Å
α=90° β=90° γ=90°
4-(Benzhydryloxy)-1-[4-(4-<i>tert</i>-butylphenyl)-4-oxobutyl]piperidinium 3,5-dinitrobenzoate
C32H40NO2,C7H3N2O6
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 10 1513-1516
a=5.9168(3)Å b=28.3733(12)Å c=21.0782(11)Å
α=90° β=97.836(5)° γ=90°
<i>N</i>,<i>N</i>-Dimethyl-[2-(2,2-diphenyl)-2-prop-2-ynyloxyacetoxy]ethylamine
C21H23NO3
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 10 1488-1492
a=9.2545(9)Å b=21.7246(19)Å c=9.4531(9)Å
α=90° β=94.763(9)° γ=90°
<i>N</i>,<i>N</i>-Dimethyl-[2-(2,2-diphenyl)-2-prop-2-ynyloxy\ acetoxy]ethylammonium 2,4,6-trinitrophenolate
C21H24NO3,C6H2N3O7
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 10 1488-1492
a=7.5208(3)Å b=8.3919(3)Å c=22.2282(7)Å
α=85.099(3)° β=84.294(3)° γ=75.117(3)°
2-benzoyloxy-5-methylbenzophenone
C21H16O3
Acta Crystallographica Section E (2004) 60, 10 o1889-o1891
a=9.2068(5)Å b=9.7961(5)Å c=10.1375(6)Å
α=94.732(4)° β=112.570(5)° γ=102.194(4)°
1,5-Bis(4-chlorophenyl)penta-1,4-dien-3-one
C17H12Cl2O
Acta Crystallographica Section E (2006) 62, 5 o1973-o1975
a=24.509(3)Å b=4.9846(5)Å c=5.8103(6)Å
α=90.00° β=90.00° γ=90.00°
Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)- 4-methylhex-4-enoate
C23H31NO7
Acta Crystallographica Section E (2004) 60, 12 o2223-o2224
a=20.784(2)Å b=9.3210(6)Å c=11.9373(11)Å
α=90.00° β=106.719(7)° γ=90.00°